Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 12 - 09 save search
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial
Published: 2021-12-09 (Crawled : 22:00) - biospace.com/
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics opioid positive results phase 3 topline
Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) CongressSuber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
OTLK | News P | $8.2 0.0% 240K
|
Health Technology
|
| O: 6.0%
H: 1.57%
C: -6.29%
trial therapeutics retina phase 3
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
Published: 2021-12-09 (Crawled : 19:00) - biospace.com/
CYDY | $0.15 0.06% 420K
|
Manufacturing
|
| O: 3.81%
H: 3.67%
C: -5.5%
covid-19 fda trial covid phase 3
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics potential opioid positive therapy results phase 3 topline
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
IOBT | $1.455 -1.02% -1.03% 57K
|
|
| O: -2.3%
H: 0.95%
C: 0.0%
trial trial results phase 1 results biotech iot phase 2 phase 3
ILLUMINATE-B Phase 3 Results of OXLUMO® (lumasiran) Published in Genetics in Medicine
Published: 2021-12-09 (Crawled : 15:30) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.29%
H: 0.31%
C: -2.8%
oxlumo genetic results phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.